Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives

References

• Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–897. doi:10.3322/caac.21456.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. doi:10.3322/caac.21559.
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191–226. doi:10.6004/jnccn.2021.0007.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004;114(7):898–907. doi:10.1172/JCI200421152.
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257. doi:10.1038/35025220.
   PubMed Web of Science ®Google Scholar
• Kern J, Steurer M, Gastl G, Gunsilius E, Untergasser G. Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer. 2009;9(1):284. doi:10.1186/1471-2407-9-284.
   PubMedGoogle Scholar
• Sato Y. The vasohibin family. Pharmaceutic (Basel). 2010;3(2):433–440. doi:10.3390/ph3020433.
   PubMedGoogle Scholar
• Horie S, Suzuki Y, Kobayashi M, Kadonosono T, Kondoh S, Kodama T, Sato Y. Distinctive role of vasohibin-1A and its splicing variant vasohibin-1B in tumor angiogenesis. Cancer Gene Ther. 2016;23(5):133–141. doi:10.1038/cgt.2016.13.
   PubMed Web of Science ®Google Scholar
• Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, Ohta H, Fujiwara T, Shimosegawa T, Sato Y. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 2009;113(19):4810–4818. doi:10.1182/blood-2008-07-170316.
   PubMed Web of Science ®Google Scholar
• Shen Z, Seppanen H, Kauttu T, Vainionpaa S, Ye Y, Wang S, Mustonen H, Puolakkainen P. Vasohibin-1 expression is regulated by transforming growth factor-beta/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells. J Interferon Cytokine Res. 2013;33(8):428–433. doi:10.1089/jir.2012.0046.
   PubMed Web of Science ®Google Scholar
• Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, Nagata H, Kikuchi E, Nakagawa K, Okada Y, et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 2013;108(10):2123–2129. doi:10.1038/bjc.2013.169.
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Kosaka T, Mikami S, Kikuchi E, Tanaka N, Maeda T, Ishida M, Miyajima A, Nakagawa K, Okada Y, et al. The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma. Clin Cancer Res. 2012;18(15):4145–4153. doi:10.1158/1078-0432.CCR-12-0073.
   PubMed Web of Science ®Google Scholar
• Yoshinaga K, Ito K, Moriya T, Nagase S, Takano T, Niikura H, Sasano H, Yaegashi N, Sato Y. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer Sci. 2011;102(2):446–451. doi:10.1111/j.1349-7006.2010.01812.x.
   PubMed Web of Science ®Google Scholar
• Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D, Shan L. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol. 2014;31(5):963. doi:10.1007/s12032-014-0963-y.
   PubMed Web of Science ®Google Scholar
• Zhou CF, Ma J, Huang L, Yi HY, Zhang YM, Wu XG, Yan RM, Liang L, Zhong M, Yu YH, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 2019;38(8):1256–1268. doi:10.1038/s41388-018-0511-x.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Ozawa S, Ninomiya Y, Koyanagi K, Oguma J, Kazuno A, Hara H, Yatabe K, Kajiwara H, Nakamura N, et al. Plasma vasohibin-1 and vasohibin-2 are useful biomarkers in patients with esophageal squamous cell carcinoma. Esophagus: Offici J Japan Esophageal Soc. 2020;17(3):289–297. doi:10.1007/s10388-020-00719-8.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Saga Y, Koyanagi T, Takei Y, Machida S, Taneichi A, Mizukami H, Sato Y, Matsubara S, Fujiwara H. Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factors. Cancer Sci. 2016;107(5):629–637. doi:10.1111/cas.12911.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Saga Y, Koyanagi T, Takei Y, Machida S, Taneichi A, Mizukami H, Sato Y, Matsubara S, Fujiwara H. The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival. Int J Oncol. 2015;47(6):2057–2063. doi:10.3892/ijo.2015.3193.
   PubMed Web of Science ®Google Scholar
• Inoue C, Miki Y, Saito-Koyama R, Kobayashi K, Seyama K, Okada Y, Sasano H. Vasohibin-1 and -2 in pulmonary lymphangioleiomyomatosis (LAM) cells associated with angiogenic and prognostic factors. Pathol Res Pract. 2022;230:153758. doi:10.1016/j.prp.2022.153758.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Zhang Y, Chen X, Wu P, Chen D. Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1. Gene Ther. 2020;27(3–4):143–156. doi:10.1038/s41434-019-0108-1.
   PubMed Web of Science ®Google Scholar
• Wang H, Deng Q, Lv Z, Ling Y, Hou X, Chen Z, Dinglin X, Ma S, Li D, Wu Y, et al. N6-methyladenosine induced miR-143-3p promotes the brain metastasis of lung cancer via regulation of VASH1. Mol Cancer. 2019;18(1):181. doi:10.1186/s12943-019-1108-x.
   PubMed Web of Science ®Google Scholar
• Zhao G, Na R, Li L, Xiao H, Ding N, Sun Y, Han R. Vasohibin-1 inhibits angiogenesis and suppresses tumor growth in renal cell carcinoma. Oncol Rep. 2017;38(2):1021–1028. doi:10.3892/or.2017.5746.
   PubMed Web of Science ®Google Scholar
• Li F, Hu Y, Qi S, Luo X, Yu H. Structural basis of tubulin detyrosination by vasohibins. Nature Structural & Molecular Biology. 2019;26(7):583–591. doi:10.1038/s41594-019-0242-x.
   PubMed Web of Science ®Google Scholar
• Mikami S, Oya M, Kosaka T, Mizuno R, Miyazaki Y, Sato Y, Okada Y. Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients. Lab Invest. 2017;97(7):854–862. doi:10.1038/labinvest.2017.26.
   PubMed Web of Science ®Google Scholar
• Sato Y. Double-face of vasohibin-1 for the maintenance of vascular homeostasis and healthy longevity. J Atheroscler Thromb. 2018;25(6):461–466. doi:10.5551/jat.43398.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501(7467):346–354. doi:10.1038/nature12626.
   PubMed Web of Science ®Google Scholar
• Xiong Y, Xiong Z, Cao H, Li C, Wanggou S, Li X. Multi-dimensional omics characterization in glioblastoma identifies the purity-associated pattern and prognostic gene signatures. Cancer Cell Int. 2020;20(1):37. doi:10.1186/s12935-020-1116-3.
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez K, Allen B, Spitzer M. Systemic immunity in cancer, Nature reviews. Nat Rev Cancer. 2021;21(6):345–359. doi:10.1038/s41568-021-00347-z.
   PubMed Web of Science ®Google Scholar
• Riley R, June C, Langer R, Mitchell M. Delivery technologies for cancer immunotherapy, Nature reviews. Drug Discovery. 2019;18(3):175–196. doi:10.1038/s41573-018-0006-z.
   Google Scholar
• Gerhard GM, Bill R, Messemaker M, Klein AM, Pittet MJ. Tumor-infiltrating dendritic cell states are conserved across solid human cancers. J Exp Med. 2021;218(1). doi:10.1084/jem.20200264.
   PubMed Web of Science ®Google Scholar
• Fu C, Jiang A. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Front Immunol. 2018;9:3059. doi:10.3389/fimmu.2018.03059.
   PubMed Web of Science ®Google Scholar
• Cozar B, Greppi M, Carpentier S, Narni-Mancinelli E, Chiossone L, Vivier E. Tumor-infiltrating Natural killer cells. Cancer Discov. 2021;11(1):34–44. doi:10.1158/2159-8290.CD-20-0655.
   PubMed Web of Science ®Google Scholar
• Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371:m3773. doi:10.1136/bmj.m3773.
   PubMed Web of Science ®Google Scholar
• Christie EL, Bowtell DDL. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii13–viii15. doi:10.1093/annonc/mdx446.
   PubMedGoogle Scholar
• Mikami S, Oya M, Kosaka T, Mizuno R, Miyazaki Y, Sato Y, Okada Y. Increased vasohibin-1 expression is associated with metastasis and poor prognosis of renal cell carcinoma patients. Lab Invest. 2017;97(7):854–862. doi:10.1038/labinvest.2017.26.
   PubMed Web of Science ®Google Scholar
• Huang W, Ren Y, Liu H. Vasohibin 1 inhibits Adriamycin resistance in osteosarcoma cells via the protein kinase B signaling pathway. Oncol Lett. 2018;15(4):5983–5988. doi:10.3892/ol.2018.8074.
   PubMed Web of Science ®Google Scholar
• Tang X, Qin Q. miR-335-5p induces insulin resistance and pancreatic islet β-cell secretion in gestational diabetes mellitus mice through VASH1-mediated TGF-β signaling pathway. J Cell Physiol. 2019;234(5):6654–6666. doi:10.1002/jcp.27406.
   PubMed Web of Science ®Google Scholar
• Serafim RB, da Silva P, Cardoso C, Di Cristofaro LFM, Netto RP, de Almeida R, Navegante G, Storti CB, de Sousa JF, de Souza FC, et al. Expression Profiling of glioblastoma cell lines reveals novel extracellular matrix-receptor genes correlated with the responsiveness of glioma patients to ionizing radiation. Front Oncol. 2021;11:668090. doi:10.3389/fonc.2021.668090.
   PubMed Web of Science ®Google Scholar
• Guo Y, Ren C, Huang W, Yang W, Bao Y. Oncogenic ACSM1 in prostate cancer is through metabolic and extracellular matrix-receptor interaction signaling pathways. Am J Cancer Res. 2022;12(4):1824–1842.
   PubMed Web of Science ®Google Scholar
• Chen CX, Luo KJ, Yang JP, Huang YC, Cardenas ER, Nicholson BJ, Jiang JX. Connexins and cAMP Cross-talk in cancer progression and metastasis. Cancers Basel. 2020;13(1):58. doi:10.3390/cancers13010058.
   PubMed Web of Science ®Google Scholar